Clinical Trial Update: Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED)

View source ↗

Summary

This completed pharmacoeconomic study evaluated the costs of treating chronic hepatitis C with peginterferon alfa-2b (PegIntron) and ribavirin (Rebetol) in the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• PegIntron (pegylated interferon alfa-2b)
• Rebetol (ribavirin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C, Chronic, Hepatitis C | Status: COMPLETED | Results posted: 2011-12-20